Blueprint Medicines (BPMC) PT Lowered to $105 at Morgan Stanley
Tweet
Share
E-mailGet Alerts BPMC Hot Sheet
Price: $129.46 --0%
Rating Summary:
11 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 21 | New: 20
Rating Summary:
11 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 21 | New: 20
Join SI Premium – FREE
Morgan Stanley analyst David Lebowitz lowered the price target on Blueprint Medicines (NASDAQ: BPMC) to $105.00 (from $112.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Freedom Broker Upgrades PrimeEnergy Resource (PNRG) to Hold
- E Ink Holdings Inc (8069:TT) PT Lowered to NT$200 at Macquarie
- Maxis Bhd (MAXIS:MK) (MAXSF) PT Raised to MYR3.82 at Nomura/Instinet
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
